Lurasidone Improves Positive Symptoms of Schizophrenia More Than Negative
Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …